Definitive Contract 75N92020C00011
Award Date 7/30/20
Potential Completion Date 1/29/22
Potential Value $21M
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
South San Francisco, CA 94080, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- Minute Molecular Diagnostics, Inc. was awarded a definitive, firm fixed price contract valued at seventeen million, five hundred ninety thousand dollars by the Department of Health and Human Services' National Institutes of Health National Heart, Lung and Blood Institute. The contract is for the RADX TECH PROJECT 2200 to develop a high-throughput, fast-turnaround, field-deployable COVID-19 molecular diagnostic system. Work will be performed in Evanston, Illinois with a period of performance...
- The National Institutes of Health awarded a $50.7 million firm fixed price modification to MicroGEM US Inc. under the RADX Tech Program. The modification extends an existing contract to maintain MicroGEM's production of 160,000 saliva-based, high-performing RT-PCR point-of-care cartridges and 1,000 portable devices per day for COVID-19 testing. The 25-minute tests and devices are non-invasive and portable. Funding comes from the Department of Health and Human Services National Institutes of...
- This is a $5,019,966 firm fixed price contract awarded by the National Heart, Lung and Blood Institute (NHLBI) of the National Institutes of Health (NIH) to Twist Bioscience Corporation, a synthetic biology company based in South San Francisco, California. The contract is for the development of a portable, rapid, and disposable COVID-19 diagnostic test using synthetic antibodies, known as the RADX TECH PROJECT 6818. This contract does not have a set-aside designation. Twist Bioscience has...
- ADL Diagnostics, Inc., operating as Anavasi Diagnostics, received a $14.9 million firm fixed-price definitive contract from the National Heart, Lung, and Blood Institute (NHLBI) to develop and deliver a low-cost, moderate-throughput COVID-19 diagnostic test. The contract, awarded November 5, 2021, with a completion date of May 4, 2023, supports the RADX Tech initiative #2180, a federal program designed to rapidly scale up testing capacity for COVID-19 across community-based settings and small...
- This is a federal contract awarded by the National Heart Lung and Blood Institute (NHLBI), a civilian agency, to Detect Inc. for the Rapid Acceleration of Diagnostics (RADx) Tech II program. The contract is valued at $8,085,388.00 and has a firm fixed price pricing type. The contract is for the "Expanded Manufacturing and Commercialization of 'Detect' COVID-19 Test: Highly Scalable, Affordable, At-Home Rapid Test" project, with a completion date of October 13, 2022. This contract...
- The National Heart, Lung, and Blood Institute awarded a $3.75 million firm fixed-price definitive contract to Avantgen Inc. on November 22, 2021, to develop a highly sensitive rapid test kit for SARS-CoV-2 that does not require a reader device under the Rapid Acceleration of Diagnostics (RADx) program. The contract, which extended through September 29, 2023, is being performed in San Diego, California. No set-aside designation was used for this award. The RADx program, a coordinated federal...
- The National Institutes of Health's National Heart, Lung and Blood Institute awarded Ginkgo Bioworks, Inc. a $6.57 million firm fixed price definitive contract to support the Rapid Acceleration of Diagnostics-Advanced Technology Platforms program. The goal of this program is to increase SARS-CoV-2 testing capacity and throughput by identifying existing testing platforms that can be used for COVID-19 diagnostics. Work will be performed by Ginkgo Bioworks in Boston, Massachusetts over a one year...
- This definitive contract from the Department of Health and Human Services' National Institutes of Health National Heart Lung and Blood Institute, valued at $34 million, was awarded to Standard Biotools Inc., doing business as Fluidigm, to support the RADX Program. Specifically, Fluidigm will provide its Advanta Dx SARS-CoV-2 RT-PCR assay for saliva to support COVID-19 testing under Project Number 6114. Performance will take place in South San Francisco, California over a period of 18 months...
- The U.S. National Institute of Biomedical Imaging and Bioengineering, part of the Department of Health and Human Services, awarded a $16,239,965.00 firm fixed price contract to Mologic Inc., a foreign-owned for-profit organization, for the Rapid Acceleration of Diagnostics (RADx) Program Tech Project #7697: SARS-CoV-2 Antigen Home Test. This contract, which does not have a set-aside designation, aims to deliver the testing products through January 2025 from Mologic's facility in Bedford, New...
- The National Heart Lung and Blood Institute (NHLBI), a civilian federal agency, awarded a $250,000 firm fixed-price purchase order to Ascella Biosystems Inc. on January 13, 2021, for support services under the RADX-TECH Work Package 1 initiative. The contract, which was not designated as a set-aside, carried an ultimate completion date of January 12, 2022, and identified performance location in Fremont, California. This award was designated as a National Interest Action related to coronavirus...